文献速递乳房整形与再造创面修复

氨磷汀与去铁胺减轻小鼠组织扩张器乳房再造放疗后真皮损伤

Therapeutic Interventions to Reduce Radiation Induced Dermal Injury in a Murine Model of Tissue Expander Based Breast Reconstruction.
PubMed 文献 · Ann Plast Surg · 2020-01-01

研究在小鼠组织扩张器乳房再造模型中,探讨放疗诱导真皮损伤机制及氨磷汀(AMF)或去铁胺(DFO)的保护作用。结果显示AMF显著改善I型胶原纤维排列和胶原合成,DFO减轻胶原二级结构异常,两者可能减少放疗相关并发症。

要点

  • 放疗导致I型胶原纤维排列紊乱显著增加(83.8% vs 22.4%),胶原/基质比降低。
  • 预防性AMF使I型胶原纤维排列紊乱降至15.9%,并保留胶原/基质比。
  • DFO显著增加β-折叠/α-螺旋比值,减轻胶原二级结构异常。

核心结论

  • 氨磷汀显著改善放疗后I型胶原纤维排列和胶原合成,去铁胺减轻胶原二级结构异常。
  • 这些治疗可能保留放疗后I型胶原的天然微结构,降低组织扩张器乳房再造联合放疗的高并发症率。

研究设计与样本

  • 雌性Lewis大鼠(n=20)分为扩张器对照组、扩张器-放疗组、扩张器-放疗-AMF组和扩张器-放疗-DFO组。
  • 所有放疗组接受28 Gy放疗,AMF组在放疗前30分钟给药,DFO组在放疗后5天使用贴片递送,恢复20天后取皮。
  • 采用原子力显微镜和拉曼光谱评估I型胶原片层组织和组织成分特性。

主要发现

  • 放疗组I型胶原纤维排列紊乱显著高于对照组(83.8% vs 22.4%;P=0.001)。
  • 放疗组胶原/基质比显著低于对照组(0.49±0.09 vs 0.66±0.09;P=0.017)。
  • AMF组I型胶原纤维排列紊乱显著低于放疗组(15.9% vs 83.8%;P=0.001),且与未放疗对照组无显著差异(P=0.122)。
  • AMF组胶原/基质比显著高于放疗组(0.69±0.10 vs 0.49±0.09;P=0.010)。
  • DFO组β-折叠/α-螺旋比显著高于放疗组(1.86±0.06 vs 1.76±0.03;P=0.038)。

临床怎么用

  • 在组织扩张器乳房再造联合放疗前,可考虑预防性使用氨磷汀以保护I型胶原结构。
  • 放疗后使用去铁胺贴片可能有助于减轻胶原二级结构异常。
  • 这些干预可能降低放疗相关真皮损伤及并发症风险,但需临床进一步验证。

局限性

  • 研究为小鼠模型,结果外推至人类需谨慎。
  • 样本量较小(n=20),可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy (XRT) induced dermal injury disrupts type I collagen architecture. This impairs cutaneous viscoelasticity, which may contribute to the high rate of complications in expander-based breast reconstruction with adjuvant XRT. The objective of this study was to further elucidate the mechanism of radiation-induced dermal injury and to determine if amifostine (AMF) or deferoxamine (DFO) mitigates type I collagen injury in an irradiated murine model of expander-based breast reconstruction. METHODS: Female Lewis rats (n = 20) were grouped: expander (control), expander-XRT (XRT), expander-XRT-AMF (AMF), and expander-XRT-DFO (DFO). Expanders were surgically placed. All XRT groups received 28 Gy of XRT. The AMF group received AMF 30 minutes before XRT, and the DFO group used a patch for delivery 5 days post-XRT. After a 20-day recovery period, skin was harvested. Atomic force microscopy and Raman spectroscopy were performed to evaluate type I collagen sheet organization and tissue compositional properties, respectively. RESULTS: Type I collagen fibril disorganization was significantly increased in the XRT group compared with the control (83.8% vs 22.4%; P = 0.001). Collagen/matrix ratios were greatly reduced in the XRT group compared with the control group (0.49 ± 0.09 vs 0.66 ± 0.09; P = 0.017). Prophylactic AMF demonstrated a marked reduction in type I collagen fibril disorganization on atomic force microscopy (15.9% vs 83.8%; P = 0.001). In fact, AMF normalized type I collagen organization in irradiated tissues to the level of the nonirradiated control (P = 0.122). Based on Raman spectroscopy, both AMF and DFO demonstrated significant differential protective effects on expanded-irradiated tissues. Collagen/matrix ratios were significantly preserved in the AMF group compared with the XRT group (0.49 ± 0.09 vs 0.69 ± 0.10; P = 0.010). β-Sheet/α-helix ratios were significantly increased in the DFO group compared with the XRT group (1.76 ± 0.03 vs 1.86 ± 0.06; P = 0.038). CONCLUSIONS: Amifostine resulted in a significant improvement in type I collagen fibril organization and collagen synthesis, whereas DFO mitigated abnormal changes in collagen secondary structure in an irradiated murine model of expander-based breast reconstruction. These therapeutics offer the ability to retain the native microarchitecture of type I collagen after radiation. Amifostine and DFO may offer clinical utility to reduce radiation induced dermal injury, potentially decreasing the high complication rate of expander-based breast reconstruction with adjuvant XRT and improving surgical outcomes.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Luby AO, Snider AE, Mandair GS, et al. Therapeutic Interventions to Reduce Radiation Induced Dermal Injury in a Murine Model of Tissue Expander Based Breast Reconstruction. Ann Plast Surg. 2020. PMID: 32187064. doi:10.1097/SAP.0000000000002264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。